RxDoctor Payments Data

Jillian Lackner

Family · Carnegie, PANPI 1487047841

Payments from drug & device makers

$887in general payments, 2019–2025

Across 52 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$247
  • Pfizer$141
  • GSK$110
  • Abbott$50
  • Bayer$41
  • AstraZeneca$38
  • plus $260 from 11 others

What the payments were for

  • Food & beverage$887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$887 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,632
Medicare patients
107
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$296,917
TrulicityDulaglutide170$239,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$128,964
OzempicSemaglutide114$121,501
XareltoRivaroxaban93$100,098
JardianceEmpagliflozin28$29,461
EntrestoSacubitril/Valsartan14$24,672
Breo ElliptaFluticasone/Vilanterol45$23,562
MounjaroTirzepatide22$22,289
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$14,987
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$14,433
Atorvastatin Calcium1,202$11,597
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$11,041
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,785
Fluticasone-SalmeterolFluticasone Propion/Salmeterol47$5,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$296,917259 claims
Lilly USA, LLCTrulicity, Mounjaro$36$261,861192 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$110$163,568226 claims
Novo NordiskOzempic$18$121,501114 claims
Johnson & JohnsonXarelto$20$100,09893 claims
AstraZenecaBreztri Aerosphere$38$6,78511 claims
AbbVieSynthroid$247$2,92368 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Carnegie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →